# Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer

> **NCT02793219** · PHASE2 · WITHDRAWN · sponsor: **The University of Texas Health Science Center, Houston**

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Sipuleucel-T
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02793219
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-12
- **Primary completion:** 2018-07
- **Final completion:** 2021-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Dendreon was sold and new company decided not to fund study.
- **Last updated:** 2017-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02793219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02793219, "Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02793219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*